JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2005;58:1315-1320; doi:10.1136/jcp.2004.022707
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Heek, N T
Right arrow Articles by Fox, J C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Heek, N T
Right arrow Articles by Fox, J C
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Bile Duct Diseases

ORIGINAL ARTICLE

Comparison of the novel quantitative ARMS assay and an enriched PCR–ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses

N T van Heek1, S J Clayton2, P D J Sturm1, J Walker2, D J Gouma, L A Noorduyn1, G J A Offerhaus1, J C Fox2

1 Department of Pathology, Academic Medical Centre Amsterdam, 1100 DD Amsterdam, The Netherlands
2 AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

Correspondence to:
Dr G J A Offerhaus
Department of Pathology, Academic Medical Center, Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands; g.j.offerhaus{at}amc.uva.nl Background: Extrahepatic biliary stenosis (EBS) has malignant and benign causes. Patients with EBS are at risk of having or developing malignancy. Accurate diagnostic tests for early detection and surveillance are needed. The sensitivity of biliary cytology for malignancy is low. K-ras mutation analysis on brush cytology is a valuable adjunct, but specificity is low. A quantitative test for K-ras mutations has been developed: the amplification refractory mutation system (ARMS).

Aim: To assess the test characteristics and additional value of ARMS in diagnosing the cause of EBS.

Methods: Brush samples from endoscopic retrograde cholangiopancreatography were collected from 312 patients with EBS. K-ras mutation analysis was performed using ARMS—allele specific amplification was coupled with real time fluorescent detection of PCR products. Results were compared with conventional cytology and K-ras mutation analysis using allele specific oligonucleotide (ASO) hybridisation, and evaluated in view of the final diagnosis.

Results: The test characteristics of ARMS and ASO largely agreed. Sensitivity for detecting malignancy was 49% and 42%, specificity 93% and 88%, and positive predictive value (PPV) 96% and 91%, respectively. The sensitivity of ARMS and cytology combined was 71%, and PPV was 93%. The specificity of ARMS could be increased to 100% by setting limits for the false positives, but reduced sensitivity from 49% to 43%.

Conclusions: ARMS can be considered supplementary to conventional cytology, and comparable to ASO in diagnosing malignant EBS. A specificity of 100% can be achieved with ARMS, which should be considered in the surveillance of patients at risk for pancreatic cancer.


Abbreviations: ARMS, amplification refractory mutation system; ASO, allele specific oligonucleotide; EBS, extrahepatic biliary stenosis; ERCP, endoscopic retrograde cholangiopancreatography; PCR, polymerase chain reaction

Keywords: K-ras; amplification refractory mutation system; allele specific oligonucleotide; brush cytology; extrahepatic biliary stenosis




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
A. Jimeno and M. Hidalgo
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.